10. The Pharmacoepidemiology of Psychiatric Medications

  1. Ming T. Tsuang3,4,
  2. Mauricio Tohen5,6 and
  3. Peter B. Jones7
  1. Philip S. Wang1,
  2. Alan M. Brookhart2,
  3. Christine Ulbricht1 and
  4. Sebastian Schneeweiss2

Published Online: 14 APR 2011

DOI: 10.1002/9780470976739.ch10

Textbook of Psychiatric Epidemiology, Third Edition

Textbook of Psychiatric Epidemiology, Third Edition

How to Cite

Wang, P. S., Brookhart, A. M., Ulbricht, C. and Schneeweiss, S. (2011) The Pharmacoepidemiology of Psychiatric Medications, in Textbook of Psychiatric Epidemiology, Third Edition (eds M. T. Tsuang, M. Tohen and P. B. Jones), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470976739.ch10

Editor Information

  1. 3

    Center for Behavioral Genomics, Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive, La Jolla CA 92039, USA

  2. 4

    Harvard Institute of Psychiatric Epidemiology & Genetics, Harvard School of Public Health, Boston, USA

  3. 5

    Department of Psychiatry, University of Texas Health Science Centre at San Antonio, USA

  4. 6

    Division of Mood and Anxiety Disorders, University of Texas Health Science Center at San Antonio, 7526 Louis Pasteur Drive, San Antonio TX 78229-3900, USA

  5. 7

    Department of Psychiatry, University of Cambridge, Box 189, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK

Author Information

  1. 1

    Division of Services and Intervention Research, National Institute of Mental Health, 6001 Executive Blvd, Room 7151, MSC 9629, Bethesda, MD 20892-9663, USA

  2. 2

    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston MA 02115, USA

Publication History

  1. Published Online: 14 APR 2011
  2. Published Print: 15 APR 2011

ISBN Information

Print ISBN: 9780470694671

Online ISBN: 9780470976739



  • pharmacoepidemiology of psychiatric medications;
  • need for rigorous pharmacoepidemiologic studies - use, risks and benefits of psychotropic medications;
  • data sources for investigations - recent psychopharmacoepidemiologic studies;
  • parent field of pharmacoepidemiology - and psychopharmacoepidemiology, young disciplines;
  • Kefauver–Harris Amendments passed in the United States - FDA's current regulatory requirements for drug approvals;
  • pharmacoepidemiologic studies - detecting outcomes, rare or after long delays;
  • health maintenance organizations (HMOs) and HMO Research Network and the Vaccine Safety Datalink programmes;
  • practice-based networks, providing information - patterns and outcomes of health services use in typical practice settings;
  • pharmaceutical companies, how products are used - for marketing purposes;
  • psychopharmacoepidemiologic studies - ensuring, use is safe, effective and cost-beneficial


This chapter contains sections titled:

  • Introduction

  • Overview of psychopharmacoepidemiology

  • Sources of data

  • Examples of recent psychopharmacoepidemiologic studies

  • Conclusions

  • Acknowledgements

  • References